Relay Therapeutics reports 60% volumetric response rate for zovegalisib in Phase 2 vascular anomalies trial

Relay announced initial Phase 2 data showing zovegalisib achieved a 60% volumetric response rate in PIK3CA-driven vascular anomalies patients at 12 weeks, with 89% investigator-reported clinical improvement and a favorable safety profile supporting chronic dosing. The positive efficacy and tolerability results advance the candidate toward expansion cohorts and suggest potential to establish a new treatment paradigm for this rare disease indication.